Results 51 to 60 of about 1,796 (202)
A case report on BPDCN: Blastic Plasmacytoid Dendritic Cell Neoplasm
World Journal of Advanced Research and Reviews, 2023 Dendritic cells are present in both lymphoid and non-lymphoid organs, which are heterogenous group of nonphagocytic and nonlymphoid immune accessory cells. Plasmacytoid dendritic cell (which has an eccentric nuclei) are subset of dendritic cells aid in secreting high levels of type 1 interferons by activation and gaining dendritic cell like morphology,
Mercy Paul M, Sukumar Naidu KD
openaire +1 more source
Blastic plasmacytoid dendritic cell neoplasm [PDF]
Blastic plasmacytoid dendritic cell neoplasm is an uncommon, aggressive hematologic neoplasm carrying a poor prognosis with a median survival of one year, making early detection vital.
Dadras, Soheil S. +4 more
core +4 more sources
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies [PDF]
, 2020 CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy cell ...
Dupont, Edouard +3 more
core +2 more sources
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN
Biology of Blood and Marrow Transplantation, 2020 Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. It commonly presents as skin lesions with or without bone marrow, lymph node or systemic involvement. Limited retrospective data have shown durable remissions after allogeneic (allo) hematopoietic cell
Muzaffar H. Qazilbash +12 more
openaire +1 more source
eJHaem, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Jad Sibai +4 more
doaj +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Rash
Journal of Community Hospital Internal Medicine Perspectives, 2023 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy derived from type 2 Dendritic cells (immature Plasmacytoid dendritic cells). It is an aggressive lymphoma and most commonly presents as nonpruritic cutaneous lesions. It can also involve the bone marrow, lymph nodes, or circulating peripheral blasts. Here we present a
Al-Alwan, Ahmad +4 more
openaire +2 more sources
HemaSphere, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with overall survival.
Livio Pagano +10 more
doaj +1 more source
Blood, 2015 Abstract Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive neoplasm for which there is still no current consensus on the best therapeutic approach. Most patients respond to intensive chemotherapy, but relapses are almost inevitable with median overall survival (OS) in the largest patient series ranging from 8 to 12 ...
Eve Poret +46 more
openaire +1 more source
Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]
Journal of Immunotherapy and Precision OncologyBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal +5 more
doaj +1 more source
Human Pathology: Case Reports, 2020 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis.
Alexis Trecourt +13 more
doaj +1 more source